Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Shares Issued (2019 - 2025)

Keros Therapeutics filings provide 7 years of Shares Issued readings, the most recent being $117000.0 for Q3 2025.

  • On a quarterly basis, Shares Issued rose 101.35% to $117000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $138000.0, a 98.86% decrease, with the full-year FY2025 number at $138000.0, down 98.86% from a year prior.
  • Shares Issued hit $117000.0 in Q3 2025 for Keros Therapeutics, up from $17000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $48.5 million in Q3 2022 to a low of -$57.4 million in Q4 2022.
  • Median Shares Issued over the past 5 years was $311000.0 (2023), compared with a mean of $879000.0.
  • The widest YoY moves for Shares Issued: up 49076.77% in 2022, down 15234.3% in 2022.
  • Keros Therapeutics' Shares Issued stood at $379000.0 in 2021, then crashed by 15234.3% to -$57.4 million in 2022, then soared by 101.4% to $804000.0 in 2023, then surged by 1410.07% to $12.1 million in 2024, then tumbled by 99.04% to $117000.0 in 2025.
  • The last three reported values for Shares Issued were $117000.0 (Q3 2025), $17000.0 (Q2 2025), and $4000.0 (Q1 2025) per Business Quant data.